Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F2 | P00734 | 18/20 | 1.00 |
| ▸ | NQO2 | P16083 | 2/20 | 0.55 |
| ▸ | F10 | P00742 | 2/20 | 0.55 |
| ▸ | SLC22A2 | O15244 | 1/20 | 0.55 |
| ▸ | PLG | P00747 | 1/20 | 0.55 |
| ▸ | PLAT | P00750 | 1/20 | 0.55 |
| ▸ | PROC | P04070 | 1/20 | 0.55 |
| ▸ | HPN | P05981 | 1/20 | 0.55 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.55 |
| ▸ | PRSS2 | P07478 | 1/20 | 0.55 |
| ▸ | PRSS3 | P35030 | 1/20 | 0.55 |
| ▸ | SLC47A2 | Q86VL8 | 1/20 | 0.55 |
| ▸ | SLC47A1 | Q96FL8 | 1/20 | 0.55 |
| ▸ | KLK1 | P06870 | 1/20 | 0.49 |
| ▸ | KLK5 | Q9Y337 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6632883 | 0.93 | F2 (0.87) | F2NQO2F10SLC22A2PLG | |
| SCHEMBL6640290 | 0.91 | F2 (0.83) | F2NQO2F10SLC22A2PLG | |
| SCHEMBL6640506 | 0.91 | F2 (0.84) | F2NQO2F10SLC22A2PLG | |
| SCHEMBL6635608 | 0.90 | F2 (0.81) | F2NQO2F10SLC22A2PLG | |
| SCHEMBL8027337 | 0.89 | F2 (1.00) | F2NQO2F10SLC22A2PLG | |
| Hydrochloric Acid SCHEMBL8029970 | 0.88 | F2 (0.79) | F2NQO2F10SLC22A2PLG | |
| SCHEMBL6633799 | 0.88 | F2 (1.00) | F2NQO2F10SLC22A2PLG | |
| Hydrochloric Acid SCHEMBL8027136 | 0.88 | F2 (0.98) | F2NQO2F10SLC22A2PLG | |
| SCHEMBL6635663 | 0.88 | F2 (1.00) | F2NQO2F10SLC22A2PLG | |
| SCHEMBL6635710 | 0.88 | F2 (0.78) | F2NQO2F10SLC22A2PLG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090075949-A1 | Use of dipyridamole in combination with antithrombotics for treatment and prevention of thromboembolic diseases | EISERT WOLFGANG | 2009-03-19 | — | — | US | claimed |
| EP-1807086-A1 | USE OF DIPYRIDAMOLE IN COMBINATION WITH ANTITHROMBOTICS FOR TREATMENT AND PREVENTION OF THROMBOEMBOLIC DISEASES | Boehringer Ingelheim International GmbH (DE) | 2007-07-18 | — | — | EP | claimed |
| WO-2006045756-A1 | USE OF DIPYRIDAMOLE IN COMBINATION WITH ANTITHROMBOTICS FOR TREATMENT AND PREVENTION OF THROMBOEMBOLIC DISEASES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2006-05-04 | — | — | WO | claimed |
| EP-1100795-B1 | DISUBSTITUTED BICYCLIC HETEROCYCLES HAVING, IN PARTICULAR, A THROMBIN INHIBITIVE EFFECT | BOEHRINGER INGELHEIM PHARMA (DE) | 2004-06-09 | — | — | EP | claimed |
| US-20020193404-A1 | Use of bicyclic heterocycles for the treatment and prevention of arterial thrombotic disease | BOEHRINGER INGELHEIM PHARMA KG (DE) | 2002-12-19 | — | — | US | claimed |
| WO-2002096425-A1 | UTILIZATION OF BICYCLIC HETEROCYCLES FOR THE TREATMENT AND PREVENTION OF ARTERIAL THROMBOTIC DISEASES | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2002-12-05 | — | — | WO | claimed |
| EP-1100795-A1 | DISUBSTITUTED BICYCLIC HETEROCYCLES HAVING, IN PARTICULAR, A THROMBIN INHIBITIVE EFFECT | BOEHRINGER INGELHEIM ZENTRALE GMBH (DE) | 2001-05-23 | — | — | EP | claimed |
| US-6121308-A | INDOLE AND BENZIMIDAZOLE ANTITHROMBOTIC COMPOUNDS, SUCH AS 1-METHYL-2-(N-(4-AMIDINOPHENYL)-AMINOMETHYL)-5-(N-(HYDROXYCARBONYLMETHYL) -QUINOLINE-8-SULPHONYLAMINO)-INDOLE | BOEHRINGER INGELHEIM KG (DE) | 2000-09-19 | — | — | US | claimed |
| WO-2000008014-A1 | DISUBSTITUTED BICYCLIC HETEROCYCLES HAVING, IN PARTICULAR, A THROMBIN INHIBITIVE EFFECT | BOEHRINGER INGELHEIM PHARMA KG (DE) | 2000-02-17 | — | — | WO | claimed |
| US-20100184729-A1 | New Pharmaceutical Compositions for Treatment of Thrombosis | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-07-22 | — | — | US | disclosed |
| US-20090075949-A1 | Use of dipyridamole in combination with antithrombotics for treatment and prevention of thromboembolic diseases | EISERT WOLFGANG | 2009-03-19 | — | — | US | disclosed |
| US-20090048173-A1 | Use Of Dipyridamole For Treatment Of Resistance To Platelet Inhibitors | EISERT WOLFGANG | 2009-02-19 | — | — | US | disclosed |
| EP-1885354-A2 | COMBINATIONS COMPRISING AT LEAST ONE DIRECT THROMBIN INHIBITOR FOR THE TREATMENT OF THROMBOSIS | Boehringer Ingelheim International GmbH (DE) | 2008-02-13 | — | — | EP | disclosed |
| EP-1807086-A1 | USE OF DIPYRIDAMOLE IN COMBINATION WITH ANTITHROMBOTICS FOR TREATMENT AND PREVENTION OF THROMBOEMBOLIC DISEASES | Boehringer Ingelheim International GmbH (DE) | 2007-07-18 | — | — | EP | disclosed |
| US-20020193404-A1 | Use of bicyclic heterocycles for the treatment and prevention of arterial thrombotic disease | BOEHRINGER INGELHEIM PHARMA KG (DE) | 2002-12-19 | — | — | US | disclosed |
| US-20020193404-A1 | Use of bicyclic heterocycles for the treatment and prevention of arterial thrombotic disease | BOEHRINGER INGELHEIM PHARMA KG (DE) | 2002-12-19 | — | — | US | disclosed |
| WO-2002096425-A1 | UTILIZATION OF BICYCLIC HETEROCYCLES FOR THE TREATMENT AND PREVENTION OF ARTERIAL THROMBOTIC DISEASES | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2002-12-05 | — | — | WO | disclosed |
| WO-2002096425-A1 | UTILIZATION OF BICYCLIC HETEROCYCLES FOR THE TREATMENT AND PREVENTION OF ARTERIAL THROMBOTIC DISEASES | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2002-12-05 | — | — | WO | disclosed |
| US-6121308-A | INDOLE AND BENZIMIDAZOLE ANTITHROMBOTIC COMPOUNDS, SUCH AS 1-METHYL-2-(N-(4-AMIDINOPHENYL)-AMINOMETHYL)-5-(N-(HYDROXYCARBONYLMETHYL) -QUINOLINE-8-SULPHONYLAMINO)-INDOLE | BOEHRINGER INGELHEIM KG (DE) | 2000-09-19 | — | — | US | disclosed |
| US-6121308-A | INDOLE AND BENZIMIDAZOLE ANTITHROMBOTIC COMPOUNDS, SUCH AS 1-METHYL-2-(N-(4-AMIDINOPHENYL)-AMINOMETHYL)-5-(N-(HYDROXYCARBONYLMETHYL) -QUINOLINE-8-SULPHONYLAMINO)-INDOLE | BOEHRINGER INGELHEIM KG (DE) | 2000-09-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090048173-A1 | Use Of Dipyridamole For Treatment Of Resistance To Platelet Inhibitors | ANXA5, F5, ANXA3 | F2 30/4885NQO2 2330/4885F10 112/4885 |
| US-20090075949-A1 | Use of dipyridamole in combination with antithrombotics for treatment and prevention of thromboembolic diseases | PEPD, PLAT, TFPI | F2 8/4885NQO2 695/4885F10 51/4885 |
| US-20100184729-A1 | New Pharmaceutical Compositions for Treatment of Thrombosis | PROC, F12, SERPINC1 | F2 4/4885NQO2 3642/4885F10 6/4885 |
| US-20020193404-A1 | Use of bicyclic heterocycles for the treatment and prevention of arterial thrombotic disease | TBXA2R, SERPINC1, TBXAS1 | F2 5/4885NQO2 89/4885F10 75/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.